Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Journal of Gastroenterology
Published in: Clinical Journal of Gastroenterology 3/2024

25-03-2024 | Hemangioma | Case Report

Transarterial embolization with bleomycin–lipiodol emulsion: a successful minimal invasive approach for giant liver hemangioma

Authors: Juferdy Kurniawan, Maria Teressa, Refael Alfa Budiman, Sahat Basana Romanti Ezer Matondang

Published in: Clinical Journal of Gastroenterology | Issue 3/2024

Login to get access

Abstract

Hemangiomas are most common benign liver tumor. Most patients have an excellent prognosis because of the small size and benign nature of tumor. On some occasions, giant liver hemangioma may cause symptoms and significant challenges due to its complication. We report a case of giant liver hemangioma treated with minimal invasive approach by transarterial embolization (TAE). Following three TAE sessions over a specific timeframe, the patient was successfully managed, addressing that TAE may be a useful alternative to hepatic surgery in such cases.
Literature
1.
2.
3.
Chang A, Ruch B, Khan A, et al. Giant liver hemangiomas: a plea for early surgical referral and resection. Case Rep Surg. 2020;2020:5923787.PubMedPubMedCentral
4.
Kalogirou M, Chourmouzi D, Dedes I, et al. Transarterial embolization for the treatment of complicated liver hemangiomas: a report of two cases and review of the literature. Clin Mol Hepatol. 2018;24:345–9.CrossRefPubMedPubMedCentral
5.
Choi BY, Nguyen MH. The diagnosis and management of benign hepatic tumors. J Clin Gastroenterol. 2005;39:401–12.CrossRefPubMed
6.
Lise M, Feltrin G, Da Pian PP, et al. Giant cavernous hemangiomas: diagnosis and surgical strategies. World J Surg. 1992;16:516–20.CrossRefPubMed
7.
Hoekstra LT, Bieze M, Erdogan D, et al. Management of giant liver hemangiomas: an update. Expert Rev Gastroenterol Hepatol. 2013;7:263–8.CrossRefPubMed
8.
Søreide JA, Deshpande R. Post hepatectomy liver failure (PHLF)—recent advances in prevention and clinical management. Eur J Surg Oncol. 2021;47:216–24.CrossRefPubMed
9.
Abdel Wahab M, El Nakeeb A, Ali MA, et al. Surgical management of giant hepatic hemangioma: single center’s experience with 144 patients. J Gastrointest Surg. 2018;22:849–58.CrossRefPubMed
10.
Liu X, Yang Z, Tan H, et al. Characteristics and operative treatment of extremely giant liver hemangioma >20 cm. Surgery. 2017;161:1514–24.CrossRefPubMed
11.
Jain V, Ramachandran V, Garg R, et al. Spontaneous rupture of a giant hepatic hemangioma—sequential management with transcatheter arterial embolization and resection. Saudi J Gastroenterol. 2010;16:116–9.CrossRefPubMedPubMedCentral
12.
Akamatsu N, Sugawara Y, Komagome M, et al. Giant liver hemangioma resected by trisectorectomy after efficient volume reduction by transcatheter arterial embolization: a case report. J Med Case Rep. 2010;4:283.CrossRefPubMedPubMedCentral
13.
Liu X, Yang Z, Tan H, et al. Long-term result of transcatheter arterial embolization for liver hemangioma. Medicine (Baltimore). 2017;96: e9029.CrossRefPubMed
14.
Ho H-Y, Wu T-H, Yu M-C, et al. Surgical management of giant hepatic hemangiomas: complications and review of the literature. Chang Gung Med J. 2012;35:70–8.PubMed
15.
Hui J, Zheyu C, Pankaj P, et al. Surgical management for giant liver hemangiomas greater than 20 cm in size. Gut Liver. 2011;5:228–33.CrossRef
16.
Kacała A, Dorochowicz M, Patrzałek D, et al. Safety and feasibility of transarterial bleomycin–lipiodol embolization in patients with giant hepatic hemangiomas. Medicina. 2023;59(8):1358.CrossRefPubMedPubMedCentral
17.
Kim JT, Heo SH, Choi SM, et al. Cerebral embolism of iodized oil (lipiodol) after transcatheter arterial chemoembolization for hepatocellular carcinoma. J Neuroimaging. 2009;19:394–7.CrossRefPubMed
18.
Hassan Y, Osman AK, Altyeb A. Noninvasive management of hemangioma and vascular malformation using intralesional bleomycin injection. Ann Plast Surg. 2013;70:70–3.CrossRefPubMed
19.
Yuan B, Zhang JL, Duan F, et al. Medium and long-term outcome of superselective transcatheter arterial embolization with lipiodol–bleomycin emulsion for giant hepatic hemangiomas: results in 241 patients. J Clin Med. 2022;11(16): 4762.CrossRefPubMedPubMedCentral
20.
Pan B, Lyu S-C, He Q. Case report: spontaneous rupture of hepatic hemangioma. Front Med. 2022;9: 918748.CrossRef
21.
Lin WC, Chang CW, Chang CW, et al. Challenges of transarterial therapy for hepatocellular carcinoma in patients with chronic kidney disease. Medicine (Baltimore). 2019;98: e17007.CrossRefPubMed
22.
Srivastava DN, Gandhi D, Seith A, et al. Transcatheter arterial embolization in the treatment of symptomatic cavernous hemangiomas of the liver: a prospective study. Abdom Imaging. 2001;26:510–4.CrossRefPubMed
23.
Metadata
Title
Transarterial embolization with bleomycin–lipiodol emulsion: a successful minimal invasive approach for giant liver hemangioma
Authors
Juferdy Kurniawan
Maria Teressa
Refael Alfa Budiman
Sahat Basana Romanti Ezer Matondang
Publication date
25-03-2024
Publisher
Springer Nature Singapore
Published in
Clinical Journal of Gastroenterology / Issue 3/2024
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-024-01948-5

Other articles of this Issue 3/2024

Clinical Journal of Gastroenterology 3/2024 Go to the issue

Case Report

Simultaneous gastric, pancreatic, and renal metastasis from poorly differentiated hepatocellular carcinoma

Case Report

Reactivation of hepatitis C virus caused by steroid monotherapy for sudden deafness

Case Report

Pazopanib-induced enteritis in a patient with renal cell carcinoma

Case Report

Verrucous gastritis-like lesion in intramucosal Helicobacter pylori-uninfected signet ring cell carcinoma with poorly differentiated adenocarcinoma

Case Report

Colonic intussusception after endoscopic mucosal resection successfully managed by endoscopic procedure

Case Report

A case of progressive xanthogranulomatous pancreatitis with splenic abscess
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits